Tolvaptan in later-stage autosomal dominant polycystic kidney disease
New England Journal of Medicine Nov 14, 2017
Torres VE, et al. - The goal of this trial was to investigate the efficacy and safety of tolvaptan in patients with later-stage autosomal dominant polycystic kidney disease (ADPKD). It was determined that tolvaptan led to a slower decline than placebo in the estimated glomerular filtration rate (GFR) over a 1-year period in the study cohort.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries